TScan Therapeutics will reduce its workforce by 75% following the pause of its hematological and autoimmune programs. | TCR-T ...

Teva Pharmaceutical's dreams of a first-in-class autoimmune blockbuster are being kept alive after the Israeli outfit’s ...

The SEC and the FDA have signed a three-year agreement to step up cooperation and information-sharing capabilities aiming to ...

Fortrea has agreed to acquire the early-phase services division of fellow CRO Worldwide Clinical Trials for $45 million. | Fortrea has agreed to acquire the early-phase services division of fellow CRO ...

Novartis has struck a deal worth up to $3.2 billion to work with Alteogen on subcutaneous drug delivery, joining Biogen and ...

AI by itself isn’t enough to develop a compelling drug; the biology also has to check out. The science behind ABS-201 came to ...

As for Alnylam’s marketed med Amvuttra (vutrisiran), approved in ATTR-CM patients last March, the company itself used the ESC Congress to trumpet a subgroup analysis in its pivotal Helios-B trial ...

GSK has linked its mRNA seasonal flu vaccine candidate to higher immune responses than conventional jabs in a phase 2 trial, ...

Eli Lilly has struck a deal to acquire Merida Biosciences for up to $2.875 billion, establishing a beachhead in efforts to ...

The 2026 IPO streak continues as Electra Therapeutics has filed to go public to support its immunology and cancer pipeline. | ...

Medtronic is recalling certain esophageal pH monitoring capsule delivery devices amid the risk of them failing whilst ...

Roche is paying oncology-focused Simcere Zaiming $75 million upfront for global rights to a preclinical trispecific antibody targeting B-cell-mediated diseases. | Roche is paying oncology-focused ...